Friday, 12 July 2019

Czech PPF Group biotech firms begin trials to extend lives of cancer patients

Radio Prague |
12 July 2019

Biotech companies within the PPF Group, controlled by Czech billionaire Petr Kellner, are reporting advances in efforts to extend the lives of cancer patients. The companies Sotio and Cytune Pharma announced on Thursday that they had started the first trial dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The first human patient began undergoing treatment at the Gustave Roussy Institute in Paris.